Breast cancer remains a major public health problem. Prospective randomized trials comparing therapies are essential to improve current therapy but, for those women unable or unwilling to participate in clinical trials, treatment plans are needed. Treatment recommendations can be based on available information from individual trials and from a large collaborative overview. This information will be reviewed with treatment recommendations presented for subpopulations of breast cancer patients.
Get full access to this article
View all access options for this article.
References
1.
BoringC.C., SquiresT.S., TongT.Cancer statistics, 1994. CA Cancer J Clin.1994; 44: 4–26.
2.
ShapiroC.L., HendersonI.C.Adjuvant therapy of breast cancer. Hematol Oncol Clin North Am.1994; 8: 213–231.
3.
HendersonI.C.Adjuvant systemic therapy of early breast cancer. In: HarrisJ.R., ed. Breast Diseases.Philadelphia, Pa: JP Lippincott Co; 1991: 427–486.
4.
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 38,896 women.Early Breast Cancer Trialists' Collaborative Group. N Engl J Med.1988; 319: 1681–1692.
5.
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.Early Breast Cancer Trialists' Collaborative Group. Lancet.1992; 339: 1–15, 71–85.
6.
ColeM.P.Prophylactic compared with therapeutic x-ray artificial menopause. In: JoslinC.A., GleaveE.N., eds. The Clinical Management of Advanced Breast Cancer. 2nd Tenovus Workshop. Cardiff, Wales: Alpha Omega Alpha Pub Co; 1970: 2–11.
7.
BryantA.J., WeirJ.A.Prophylactic oophorectomy in operable instances of carcinoma of the breast. Surg Gynecol Obstet.1981; 153: 660–664.
8.
RavdinR.G., LewisonE.F., SlackN.H.Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet.1970; 131: 1055–1064.
9.
Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial.Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet.1993; 341: 1293–1298.
10.
BiancoA.R., Del MastroL., GalloC.Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer.1991; 63: 799–803.
11.
TormeyD.C., GrayR., GilchristK.Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. Cancer.1990; 65: 200–206.
12.
BonadonnaG., ValagussaP., RossiA.Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat.1985; 5: 95–115.
13.
FisherB., ShermanB., RocketteH.L-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers. Cancer.1979; 44: 847–857.
14.
FowbleB.L., SchultzD.J., OvermoyerB.The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys.1994; 30: 23–33.
15.
AdamiH.O., MalkerB., HolmbergL.The relation between survival and age at diagnosis in breast cancer. N Engl J Med.1986; 315: 559–563.
16.
de la RochefordiereA., AsselainB., CampanaF.Age as a prognostic factor in premenopausal breast carcinoma. Lancet.1993; 341: 1039–1043.
17.
Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Nolvadex Adjuvant Trial Organisation. Br J Cancer.1988; 57: 608–611.
18.
FisherB., CostantinoJ., RedmondC.A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med.1989; 320: 479–484.
19.
BonadonnaG., ValagussaP.Systemic therapy in resectable breast cancer. Hematol Oncol Clin North Am.1989; 3: 727–742.
20.
FisherB., RedmondC., DimitrovN.V.A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med.1989; 320: 473–478.
21.
MansourE.G., GrayR., ShatilaA.H.Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an intergroup study. N Engl J Med.1989; 320: 485–490.
22.
Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer: The Ludwig Breast Cancer Study Group.N Engl J Med.1989; 320: 491–496.
23.
GoldhirschA., CastiglioneM., GelberR.D.A single perioperative adjuvant chemotherapy course for node-negative breast cancer: five year results of trial V. Monogr Natl Cancer Inst.1992; 11: 89–96.
24.
Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients: the International Breast Cancer Study Group.Ann Oncol.1990; 1: 30–35.
25.
GlickJ.H., GelberR.D., GoldhirschA.Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst.1992; 84: 1479–1485.
26.
FisherB., RedmondC., WickerhamD.L.Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol.1989; 7: 572–582.
27.
MissetJ.L., Gil-DelgadoM., CholletP.Ten years results of the French trial comparing adriamycin (ADM), vincristine (VCR), 5-fluorouracil (5-FU) and cyclophosphamide (CPM) to standard CMF as adjuvant therapy for node-positive breast cancer. Proc Annu Meet Am Soc Clin Oncol.1992; 11: A41.
28.
FisherB., BrownA.M., DimitrovN.V.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjvant Breast and Bowel Project B-15. J Clin Oncol.1990; 8: 1483–1496.
29.
CarpenterJ.T., Velez-GarciaE., AronB.S.Prospective randomized comparison of cyclophosphamide, doxorubicin (adriamycin) and fluorouracil (CAF) vs cyclophosphamide, methotrexate and fluorouracil (CMF) for breast cancer with positive axillary nodes: a Southeastern Cancer Study Group study. Proc Annu Meet Am Soc Clin Oncol.1991; 10: A54.
30.
WoodW.C., BudmanD.R., KorzunA.H.Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med.1994; 330: 1253–1259.
31.
MussH.B., ThorA.D., BerryD.A.c-erb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med.1994; 330: 1260–1266.
32.
DimitrovN., AndersonS., FisherB.Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): findings from NSABP B-22. Proc Annu Meet Am Soc Clin Oncol.1994; 13: A58.
33.
PetersW.P., RossM., VredenburghJ.J.High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol.1993; 11: 1132–1143.
